Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ) has announced the accelerated availability and development of critical research tools for Nipah virus (NiV) in response to recent reports of infections in West Bengal, India. The move aims to support the global scientific community in combating this high-mortality pathogen, which the World Health Organization (WHO) classifies as a priority pathogen due to its epidemic potential and fatality rate of 40% to 75%.
Nipah virus, a member of the Paramyxoviridae family, currently has no approved vaccines or specific antiviral treatments, making the demand for high-quality, biologically active reagents critical for developing effective countermeasures. Sino Biological has launched a series of high-purity NiV G and F proteins, essential for understanding viral entry mechanisms and screening therapeutic antibodies. The company is also fast-tracking development of NiV N proteins and pre-fusion and post-fusion F trimer proteins, based on the most recently reported strains to offer improved sequence relevance. Additionally, ProPure™ endotoxin-free versions of NiV G and F proteins are available for vaccine research applications where immunogen purity and endotoxin control are critical.
“Our mission is to provide the scientific community with the highest quality tools as rapidly as possible when emerging infectious diseases threaten global health,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US. “By expanding our NiV portfolio, we aim to empower researchers to streamline vaccine discovery and diagnostic breakthroughs.”
For more information on Sino Biological’s Nipah virus reagents, visit https://www.sinobiological.com/research/virus/nipah-virus and https://www.sinobiological.com/research/virus/niv-proteins-reagent. The original press release is available at https://www.newmediawire.com.
